H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc. in a transaction valued at approximately $2.6 billion equity value and $2.5 billion net of cash, on a fully diluted basis.   The acquisition of Longboard marks a strategic milestone for Lundbeck, enhancing and complementing its Focused Innovator strategy and advancing its goal of building a neuro-rare disease franchise.   Through the acquisition of Longboard, Lundbeck gains access to bexicaserin, a novel 5-HT2C agonist in d...